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Second-line treatments boost overall survival in advanced gastric cancer (AGC). However,
there is a paucity of information as to patterns of use and the results achieved in actual clini-
cal practice.
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Materials and methods
The study population comprised patients with AGC in the AGAMENON registry who had
received second-line. The objective was to describe the pattern of second-line therapies
administered, progression-free survival following second-line (PFS-2), and post-progres-
sion survival since first-line (PPS).
Results
2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245
(10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-
line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9–3.3) and 5.8 months (5.5–6.3), respec-
tively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramuciru-
mab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and
ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months;
polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7
months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Cor-
relation between PFS since first-line and OS was moderate in the series as a whole (Ken-
dall’s τ = 0.613), lower in those subjects who received second-line (Kendall’s τ = 0.539),
especially with ramucirumab+CT (Kendall’s τ = 0.413).
Conclusion
This analysis reveals the diversity in second-line treatment for AGC, highlighting the effec-
tiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum rein-
troduction; both strategies endorsed by recent clinical guidelines.
Introduction
Advanced gastric cancer (AGC) is the third leading cause of cancer death worldwide [1]. Che-
motherapy (CT) is capable of improving overall survival (OS) and quality of life for individuals
with AGC compared to best supportive care (BSC) [2]. In first line, platin-fluoropyrimidine
schedules are the most widely recommended option [3], whereas the standard of care is the
combination of trastuzumab and cisplatin-fluoropyrimidine for tumors that amplify or over-
express human epidermal growth factor receptor-2 (HER2+) [4]. The benefit of first-line is
limited; up to 25%-30% display progression at their first evaluation of response [5] and median
progression-free survival (PFS) is 4–7 months [2], with approximately 50% of patients in suit-
able conditions to receive second-line treatment after progression since first-line [6, 7].
Numerous drugs have proven activity in second-line for AGC [8, 9]. Thus, a small random-
ized trial (NCT00144378) confirmed for the first time that the use of irinotecan vs BSC in sec-
ond line discreetly prolonged OS [6]. In the COUGAR-2 study, docetaxel incremented OS
versus BSC and likewise demonstrated a benefit in quality of life [10]. Both drugs again
improved OS compared to BSC in a phase III trial [7], while the WJOG-4007 study detected
no differences between them or between paclitaxel and irinotecan [9]. More recently, the use
of ramucirumab plus paclitaxel vs paclitaxel in second line was seen to increase OS in all sub-
groups in the RAINBOW trial [11]. For its part, the REGARD study corroborated a gain in OS
with ramucirumab vs BSC [12]. Both studies with ramucirumab were bolstered by favorable
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quality of life analyses, as well as real-world data [13–15]. This positions ramucirumab as the
recommended second-line strategy, whether in combination or monotherapy [16]. There are
minimal data concerning how the use of the various alternatives available for second-line treat-
ment has evolved, in addition to their efficacy in actual clinical practice [17].
Moreover, pembrolizumab has demonstrated efficacy in a second line study of carcinoma
of the esophagus and of the gastroesophageal junction, in the pre-specified subgroup of
PDL1-CPS�10 [18], while efficacy in second-line was unproven for advanced gastric or gas-
tro- gastroesophageal junction adenocarcinoma in the KEYNOTE-061 phase III study [19].
Treatment in second and successive lines for HER2+ tumors does not currently differ from
the rest, given the absence of evidence in favor of anti-HER2 therapy [20, 21]. Nevertheless,
these tumors are molecularly dissimilar.
Based on retrospective analysis, certain individuals who do not receive first-line treat-
ment until progression might profit from reintroducing platin-fluoropyrimidine doublets,
when the treatment-free interval exceeds three months [22]. This subgroup of patients is
excluded from most recent second-line clinical trials for AGC [11, 12], and most updated
clinical guidelines consider reintroduction of the first-line to be an appropriate alternative
[16].
Likewise, treatment options with proven efficacy exist in various third-line scenarios [23–
25]. This availability of options beyond first line makes survival susceptible to the outcomes
associated with successive lines of treatment, which could have implications when designing
clinical trials. We must therefore revisit the value of intermediate endpoints, such as PFS, as
surrogates for OS [26–30].
Against this backdrop, we have conducted this study to evaluate patterns of use and out-




The patient population assessed derive from the Spanish AGAMENON registry that enlists the
collaboration of 34 Spanish hospitals and one center in Chile and recruits consecutive cases of
unresectable or metastatic, locally advanced adenocarcinoma of the stomach, gastroesophageal
junction, or distal esophagus [31–39].
Eligibility criteria are: patients with AGC, aged>18 years, who received first-line treatment
with polyCT routinely administered in clinical practice (two- or three-agent schedule, with or
without platin) [40], and experienced tumor progression or died during first-line treatment.
Those cases that had completed neoadjuvant or adjuvant treatment before 6 months were
excluded.
Data are managed through a website (http://www.agamenonstudy.com/) consisting of fil-
ters and a query-generating system to guarantee reliability and control missing and inconsis-
tent data, as well as errors. Telephone and on-line monitoring (PJF) further guarantee data
quality.
Objectives
The primary objective of this study was to describe the pattern of second-line therapies admin-
istered from 2008 onward and the associated outcomes. The secondary objective was to assess
the correlation between PFS and OS over time, in terms of clinical-pathological variables and
use of second lines.
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Variables
Post-progression survival (PPS) and PFS-2 were defined as the time between initiation of sec-
ond-line and all-cause mortality or progression, respectively, censuring those event-free indi-
viduals at the time of the last follow up. OS and PFS-1 were defined as the interval between
commencement of first-line treatment and death for any cause or progression, respectively,
censoring at last follow up.
Second-line strategies were categorized as: (1) platinum-reintroduction, defined as provid-
ing a second-line platin-based schedule to individuals who had received platin in first-line
with no evidence of progression when plantin was stopped; (2) maintenance of trastuzumab
post-progression, consisting of changing the backbone of CT in progression to first-line with-
out discontinuing trastuzumab; (3) regimens containing ramucirumab included use of pacli-
taxel, irinotecan, or other cytotoxics in combination with ramucirumab; (4) ramucirumab in
monotherapy; additionally, patients could receive (5) monoCT or (6) polyCT.
Statistics
Survival functions were Kaplan-Meier estimates. Correlation between PFS and OS was quanti-
fied by Kendall’s τ associated with Clayton’s copula models for bivariate survival data. Sensitiv-
ity to second line was evaluated using multivariable binary logistic regression (covariates were
HER2 status, histological subtype, signet ring cells, hepatic tumor burden, number of meta-
static sites, and interval of time since withdrawal of platin in first-line). Continuous variables
were analyzed by means of restricted cubic splines. Treatment effect was appraised using a
Cox multivariable proportional hazards model. No data-driven criteria were used for the
model specification. The covariates for the multivariable model were chosen by theoretical
considerations, as recommended in the literature [41]. Thus, ECOG PS (<2,�2), Lauren’s his-
topathological subtype (intestinal, diffuse), number of metastatic sites (�2,>2), liver tumor
burden (�50, >50%), HER2 status (negative, positive), PFS-1, and best response to first-line
(complete or partial response, stable disease, progressive disease) were used as confounding
factors. Restricted cubic splines were used to model the non-linear effect of PFS-1. Given that
it is an observational, fixed sample size study, inferences should be interpreted in accordance
with the magnitude of the CI with a descriptive purpose (hypothesis generator). Analyses were
performed with the R v3.1.6 software package, with rms and Copula.surv libraries [42, 43].
Ethics statement
This study has Compliance with Ethical Standards. This study was approved in November, 4 th
2014 by the Ethics, Research and Investigation Committee in Hospital Morales Meseguer, Mur-
cia, Spain. The Research Ethics Committee from Morales Meseguer General University Hospital
first, and then all the rest of Autonomous Communities and participating hospitals approved the
study. The Spanish Agency of Medicines and Medical Devices categorized this study as a post-
marketing, prospective follow-up study. In every alive prospective or retrospective registered
patient, written informed consent was obtained in order to be included in the study. Participants
who were not alive at data collection had previously provided written informed consent to use
their medical records for the purposes of research. This was carried out according to the require-
ments stated in the international guidelines regarding carrying out epidemiological studies and
put forth in the International Guidelines for Ethical Review of Epidemiological Studies (Council
for the International Organizations of Medical Sciences–CIOMS-, Geneva, 1991), as well as the
Declaration of Helsinki (Seoul revision, October, 2008). This document defines the principles
that must be scrupulously respected by any and all personas involved in the research. The treat-
ment, communication, and conveyance of the personal data of all participants was adapted to
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the Organic Law 3/2018, dated December 5, regarding the Protection of Personal Data requiring
approval by a Clinical Research Ethics Board (CREB).
Results
Patients and second-line treatments
At the time of analysis, 2311 cases had been recorded that met eligibility criteria, 2066 progres-
sion events since first-line (89.3%) and 2103 deaths (90.9%). Of the latter, 245 (10.6%) died
during first-line. Median PFS-1 was 5.6 months (95% CI, 5.5–5.9), while median OS was 10.2
months (95% CI, 9.8–10.7).
Second-line therapy was given to 1326/2066 (64.1%); 366 (17.7%) received three lines, and 98
(4.7%), four or more. Baseline characteristics are summarized in Table 1. The most common strate-
gies were: monoCT 56.9% (n = 755), polyCT 15.0% (n = 199), ramucirumab+CT 12.6% (n = 167),
platinum-reintroduction 8.3% (n = 110), trastuzumab-continuing schedules 6.1% (n = 81), and
ramucirumab monotherapy 1.1% (n = 14). S1 Table displays characteristics per strategy used.
In subjects treated with platinum-reintroduction, the reason for discontinuing platinum in
first-line before progression was: having completed the number of cycles established by their
center’s protocol (71.8%), toxicity (18.2%), patient request (2.7%), and other reasons (7.3%).
Of the participants who received trastuzumab in second-line, 14/81 (17.3%) had not
received it in first-line. Trastuzumab was withheld from those 14 patients in first-line because
their HER2 status was unavailable (7 cases); due to cardiac comorbidity (n = 3), or oncologist’s
decision (n = 4). S2 Table shows the data of use of these strategies by HER2 status.
Fig 1 illustrates the usage trend of these strategies over time, revealing that the only one
with an upward trend is the incorporation of ramucirumab from 2012 onward.
Response rate to second lines
The response rate to second lines was 12.7% (n = 168); 28.5% had stable disease (n = 378) and
the disease control rate (response or stable disease) was 41.2%. Progression occurred in 55.1%
(n = 731) and information regarding response was unavailable for 3.7% (n = 49) of the cases.
Fig 2 illustrates response rates by second-line strategy and HER2 status. For descriptive pur-
poses, the probability of response to second-line has been represented depending on histopath-
ological subtype, prior response to first-line, HER2 status and platin-free interval (S1–S3 Figs;
S3 Table). The underlying model suggests differences according to these features. For instance,
in diffuse tumors not responding previously to platin, the odds of achieving response to ramu-
cirumab+CT vs monoCT increased as a function of platin-free interval: odds ratio (OR) 1.53
(95% CI, 0.69–3.72) at one month; OR 2.22 (95% CI, 1.30–3.81) at three months, and OR 2.90
(95% CI, 1.41–5.97) at six months. Plots with the probability of response for HER2+ and
HER2-negative tumors can be seen in S2 and S3 Figs, respectively.
Survival endpoints in second lines
At the time of analysis, 93.7% had suffered a progression event and 86.2% died after second-
line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9–3.3) and 5.8 months (95% CI, 5.5–6.3),
respectively. Fig 3 presents survival for both endpoints.
Survival endpoints for each treatment group are laid out in Table 2. The highest median
PFS-2 and PPS were obtained with platinum-reintroduction: 4.2 (95% CI, 3.3–5.0) and 6.7
months (95% CI, 5.5–10.2) and with ramucirumab+CT: 4.1 (95% CI, 3.4–5.2) and 6.5 months
(95% CI, 5.5–8.7), respectively. In the case of HER2+ tumors, trastuzumab-containing regi-
mens achieved a median PFS-2 of 4.8 months (95% CI, 3.6–5.7) and PPS of 10.5 months (95%
PLOS ONE Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
PLOS ONE | https://doi.org/10.1371/journal.pone.0235848 July 31, 2020 5 / 16
Table 1. Characteristics at the time of diagnosis.
Variables Total, n (%),
n = 2311
Patients receiving 2nd-line, n (%),
n = 1326
Age, median (range) 64 (20–89) 63 (20–86)
Sex, female 672 (29.1) 370 (27.9)
Lauren subtype
Diffuse 745 (32.2) 409 (30.8)
Intestinal 991 (42.8) 589 (44.4)
Mixed 107 (4.6) 61 (4.6)
Not Available 468 (20.2) 267 (20.1)
Signet ring cells 657 (28.4) 354 (26.7)
HER2-positive 502 (21.7) 318 (23.9)
ECOG-PS basal
0 533 (23.2) 361 (27.2)
1 1457 (63.0) 849 (64.0)
�2 321 (12.8) 114 (8.8)
Tumor stage at diagnosis, locally advanced
unresectable
134 (18.1) 74 (5.5)
Histological grade
1 225 (9.7) 152 (11.5)
2 628 (27.2) 361 (27.2)
3 933 (40.4) 525 (39.6)
Not available 525 (22.7) 288 (21.7)
First-line treatment
Anthracycline-based 464 (20.1) 285 (21.5)
Cisplatin-based doublet 472 (20.4) 302 (22.8)
Docetaxel-based 276 (11.9) 154 (11.6)
Irinotecan-based 43 (1.9) 25 (1.9)
Oxaliplatin-based 911 (39.4) 498 (37.6)
Other 145 (6.3) 62 (4.7)
Metastases sites
Ascites 545 (23.6) 289 (21.8)
Peritoneal 1011 (43.7) 559 (42.2)
Bone 235 (10.2) 112 (8.4)
Lung 308 (13.3) 185 (14.0)
Liver 876 (37.9) 522 (39.4)
Burden of liver disease >50% 453 (19.6) 247 (18.6)
Number of metastases >2 629 (27.2) 332 (25.0)
Primary tumor site
Esophagus 183 (7.9) 113 (8.5)
GEJ 306 (13.2) 166 (12.5)
Stomach 1822 (78.8) 1046 (79.0)
PFS-1 5.6 (5.4–5.9) 6.8 (6.5–7.1)
Best response to first-line
Complete response 22 (1.0) 18 (1.4)
Partial response 661 (28.6) 465 (35.1)
Stable disease 1028 (44.5) 570 (43.0)
Progression disease 600 (26.0) 273 (20.6)
Abbreviations: ECOG-PS, Eastern Cooperative Group Performance Status; GEJ, gastroesophageal junction.
https://doi.org/10.1371/journal.pone.0235848.t001
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CI, 5.5–12.1). In a sensitivity analysis, after excluding 14 subjects without first-line trastuzu-
mab, the remaining patients obtained a similar median PFS-2/PPS, 4.80 (CI 95%, 3.45–5.75)
and 10.8 months (CI 95%, 7.1–14.6) respectively. MonoCT yielded the worst results with
median PFS-2 of 2.6 months (95% CI, 2.4–2.7) and PPS of 5.1 months (95% CI, 4.6–5.7). In
the multivariable Cox model, taking monoCT as reference, ramucirumab+CT (HR 0.62; 95%
CI, 0.51–0.74), platinum-reintroduction (HR 0.76; 95% CI, 0.61–0.94), polyCT (HR 0.81; 95%
CI, 0.69–0.96), and trastuzumab+CT (HR 0.58, 95% CI; 0.44–0.77, in HER2+) were associated
with better PFS-2. The data as per HER2 subtype are detailed in Table 2 and Fig 4.
Correlation of PFS & OS with each treatment strategy
The correlation between PFS-1 and OS is moderate in the complete series (n = 2311, Kendall’s τ =
0.613), lower in individuals who received a second-line (Kendall’s τ = 0.539). The possibility of
having effective second lines available dilutes the surrogate value of PFS-1, principally in individuals
who receive CT-ramucirumab. Correlations for each treatment strategy are as follows: ramuciru-
mab+CT (Kendall’s τ = 0.413), polyCT (Kendall’s τ = 0.503), monoCT (Kendall’s τ = 0.539), trastu-
zumab+CT (Kendall’s τ = 0.566), and platinum-reintroduction (Kendall’s τ = 0.585) (S4 Table).
Discussion
Within the context of AGC, second-line therapy has been proven to enhance OS compared to
BSC to a statistically significant extent [44]. In a meta-analysis of 10 clinical trials, polyCT was
Fig 1. Time trends in the use of second-line schedules based on HER2 status. Abbreviations: polyCT, polychemotherapy; monoCT, monochemotherapy; Ram+CT,
ramucirumab+chemotherapy.
https://doi.org/10.1371/journal.pone.0235848.g001
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more effective than monoCT [45], while a network meta-analysis suggests that the combina-
tion of paclitaxel+ramucirumab is most likely to be the best schedule available to date [46].
However, data with reference to real-world use of second lines (without the usual clinical trial
selection biases) are scant. Moreover, there is a paucity of information about the strategies cli-
nicians apply pragmatically, such as platinum-reintroduction or using trastuzumab beyond
progression.
To investigate these aspects, we evaluated the use of second-line in the 64.1% of the AGC
registry patients who received it, a percentage similar to that observed by other authors [6, 7].
The individuals who received second-line tended to be those who had benefitted most from
first-line, with longer PFS-1.
Our data corroborate that polyCT and CT+ramucirumab is superior to monoCT in daily
practice [45, 46]. Bearing in mind the safety profile of each strategy in indirect comparisons,
and the available scientific evidence, this would endorse the established role of ramucirumab+-
paclitaxel as the current standard of second-line treatment in AGC. The AGAMENON data
endorse this consideration, by revealing a trend toward increased use of ramucirumab, alone
and in combination, compared to the remaining second-line strategies, which are declining.
Furthermore, the study indicates that histopathological subtype, therapy administered, time
since platin withdrawal, and better response to first-line might be among the factors associated
with response. In particular, chemosensitivity to second-line are continuously and non-
Fig 2. Response rates according to HER2 and strategy. Abbreviations: Pl reint, platinum reintroduction; poly-CT, polychemotherapy; P, paclitaxel; Ram,
ramucirumab; CT, chemotherapy; Trastu, trastuzumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available.
�Paclitaxel was the cytotoxic used in all patients with HER-negative tumors who received ramucirumab+chemotherapy, whereas paclitaxel and other cytotoxics were
associated with ramucirumab in HER+ tumors.
https://doi.org/10.1371/journal.pone.0235848.g002
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linearly related to the platin-free period. PFS-1 is a known and consistent predictive factor dur-
ing second-line therapy [44, 47]. Diffuse tumors are more refractory to second-line treatment
than the intestinal subtype, although this depends on the interaction with the platin-free inter-
val. Thus, even in adverse scenarios, such as treatment-resistant diffuse tumors, the probability
of response is twofold in those exposed to ramucirumab+CT vs monoCT, indicating that treat-
ment choice is key to achieving benefit.
Based on retrospective analysis, reintroduction of the same drug combination should be
contemplated for patients in whom first-line treatment was discontinued and time to progres-
sion exceeded three months, provided that any toxicity issues have been resolved [22] and as
recommended in the most recently updated guidelines [16]. In this registry, the reintroduction
of firs-line platin-based therapy (10% of Her2- patients) was associated with the highest disease
control rate and median PPS. These results are comparable to those of the study by Okines
Fig 3. Survival curves for PFS-2 and PPS (n = 1326). Abbreviations: PFS-2, progression-free survival to second-line of treatment; PPS, post-progression survival.
https://doi.org/10.1371/journal.pone.0235848.g003
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et al that revealed that the reintroduction of platin was associated with median PFS-2 and PPS
of 3.9 and 6.6 months, respectively [22], depending on prior chemosensitivity to platin, platin-
free interval, and histological subtype. Therefore, given that platin is sometimes discontinued
due to cumulative toxicity, proceeding with fluoropyrimidine until progression [48], platin
reintroduction might be an especially useful option in intestinal tumors, sensitive to platin in
first-line, with a prolonged platin-free interval and in the absence of residual toxicity.
Another strategy arising in this real world evidence analysis is that of using trastuzumab fol-
lowing progression, which in this registry accounts for 25.5% of HER+ tumors, although evi-
dence for trastuzumab in second-line treatment of AGC is lacking [49, 50]. Likewise, our data
corroborate the favorable prognostic effect of HER2+ status that is maintained beyond first-
line [34]. Still, the reader must be mindful of the current lack of positive results in clinical trials
that have assessed anti-HER2 therapy in second-line [20, 21], as well as the confirmed benefit
of ramucirumab in cases in which trastuzumab was administered in first-line [51].
Finally, we have examined the surrogate function of PFS-1 within the context of the avail-
ability of treatment strategies after first-line. OS has traditionally been the gold-standard end-
point in clinical trials of first-line therapy for AGC; nonetheless, PFS continues to be routine
in various randomized AGC studies [26–28]. The advantages of PFS include shortened study
duration, smaller sample size, and the absence of interference of post-progression therapies.
Overall, the use of intermediate endpoints calls for statistical proof of the validity of the surro-
gate, as well as the justification of the clinical value that delaying progression has for the
patient’s quality of life [52]. Our data reveal that the correlation between PFS-1 and OS is mod-
erate in actual practice, with a magnitude slightly lower than that reported in the literature
[53]. In fact, the possibility of having effective second lines available dilutes the surrogate value
of PFS-1, principally in individuals who receive CT-ramucirumab. Bearing in mind the grad-
ual increase in the use of ramucirumab in our series, this would call into question the appro-
priateness of substituting OS for PFS-1 in studies of first line in AGC.
Table 2. Survival endpoints based on the strategy for HER+ and HER-negative tumors.
Variables n/events Median PFS-2, months (95% CI) n/events Median PPS, months (95% CI)
All
Mono-CT 755/723 2.6 (2.4–2.7) 755/677 5.1 (4.6–5.7)
Poly-CT 199/194 3.4 (2.7–3.9) 199/172 6.3 (5.6–7.2)
Ram-CT 167/139 4.1 (3.4–5.2) 167/104 6.5 (5.5–8.7)
Plat reintroduction 110/104 4.2 (3.3–5.0) 110/99 6.7 (5.5–10.2)
HER2-negative
Ram 14/11 2.8 (1.8-NA) 14/10 5.0 (3.0-NA)
Mono-CT 592/566 2.6 (2.4–2.8) 592/527 4.9 (4.3–5.4)
Poly-CT 177/172 3.4 (2.7–4.8) 177/157 6.2 (5.5–7.1)
Ram-CT 125/104 3.8 (3.3–5.1) 125/84 6.5 (5.1–9.4)
Plat reintroduction 100/95 4.1 (3.2–4.8) 100/91 6.6 (5.4–9.8)
HER2-positive
Mono-CT 163/157 2.7 (2.4–3.2) 163/150 6.7 (5.2-NA)
Poly-CT 22/22 3.0 (2.5–5.7) 22/20 8.6 (5.0–14.9)
Ram-CT 42/35 4.7 (3.2–6.3) 42/30 7.3 (5.5–12.1)
CT + Trastuzumab 81/72 4.8 (3.6–5.7) 81/66 10.5 (5.5–12.1)
Plat reintroduction 10/9 5.2 (3.1-NA) 10/8 11.7 (7.3–13.3)
Abbreviations: Ram, ramucirumab; Plat, platinum; CT, chemotherapy; PFS-2, progression-free survival to second-line of treatment; PPS, post-progression survival.
https://doi.org/10.1371/journal.pone.0235848.t002
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There are several limitations implicit in observational studies, such as this one, in which the
criteria that mediate in the decisions regarding second lines depend on the evolution of the
disease that are not initially present and, as such, are difficult to capture in a registry of this
kind. In addition, patients in this registry received first-line treatment with polyCT, excluding
more fragile patients who were only candidates for monoCT. Nevertheless, survival endpoints
and baseline characteristics are adequately typified through regular reviews and updating of
the information.
Fig 4. Survival functions since initiation of second-line by HER2 status and treatment strategy. Abbreviations: PFS-2, progression-free survival to second-line of
treatment; PPS, post-progression survival; CT, chemotherapy; Pacli, paclitaxel.
https://doi.org/10.1371/journal.pone.0235848.g004
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Conclusion
In short, our study provides the largest real world practice data set regarding the use of second
lines for AGC, backing up the scientific evidence derived from previous clinical trials and
smaller retrospective analyses. Our analysis reveals the diversity in second-line treatment for
AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of
patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines. Addi-
tionally, it disputes the role of PFS as a surrogate for OS with the progressive incorporation of
more efficacious strategies in successive lines of treatment.
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